Testing radiation for borderline pancreatic surgery using a tiny implant
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early trial studies whether adding targeted radiation during or around pancreatic surgery is safe and may improve outcomes for people with borderline resectable pancreatic cancer. It is mainly looking at feasibility and safety while treating close to the tumor but not spreading (no metastasis).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and are an adult (over 18).
- You are able to undergo surgery with anesthesia (for a Whipple or distal pancreatectomy).
- Your pancreatic cancer is not metastatic, and it is considered borderline resectable or locally advanced.
- You recently had chemo and radiation before surgery (about 4 to 10 weeks earlier).
- Your chemo/radiation plan fits specific types and timing (gemcitabine + nab-paclitaxel or FOLFIRINOX; radiation type and dose limits).
- You are not pregnant or breastfeeding, and you have no current plan to join another trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
This study tests a personalized form of stereotactic radiation therapy (high-precision radiation planned to fit your tumor) after you’ve had some chemotherapy. It aims to treat pancreatic tumors while limiting exposure to nearby healthy organs.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a precise type of radiation therapy guided by MRI for people with locally advanced pancreatic cancer. It aims to treat the tumor while protecting nearby healthy tissue, potentially improving outcomes after chemotherapy.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.